Xspray Pharma Ab Stock Book Value Per Share
XSPRAY Stock | SEK 42.40 0.45 1.07% |
XSpray Pharma AB fundamentals help investors to digest information that contributes to XSpray Pharma's financial success or failures. It also enables traders to predict the movement of XSpray Stock. The fundamental analysis module provides a way to measure XSpray Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XSpray Pharma stock.
XSpray |
XSpray Pharma AB Company Book Value Per Share Analysis
XSpray Pharma's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current XSpray Pharma Book Value Per Share | 24.95 X |
Most of XSpray Pharma's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XSpray Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition |
In accordance with the recently published financial statements, the book value per share of XSpray Pharma AB is about 24.945 times. This is 1567.35% lower than that of the Healthcare sector and 110.03% lower than that of the Biotechnology industry. The book value per share for all Sweden stocks is 98.71% higher than that of the company.
XSpray Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XSpray Pharma's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XSpray Pharma could also be used in its relative valuation, which is a method of valuing XSpray Pharma by comparing valuation metrics of similar companies.XSpray Pharma is currently under evaluation in book value per share category among its peers.
XSpray Fundamentals
Return On Equity | -0.24 | |||
Return On Asset | -0.14 | |||
Operating Margin | (116.51) % | |||
Current Valuation | 1.16 B | |||
Shares Outstanding | 22.68 M | |||
Shares Owned By Insiders | 47.42 % | |||
Shares Owned By Institutions | 27.60 % | |||
Price To Book | 2.35 X | |||
Price To Sales | 1,206 X | |||
Gross Profit | 656 K | |||
EBITDA | (87.82 M) | |||
Net Income | (96.7 M) | |||
Cash And Equivalents | 192.85 M | |||
Cash Per Share | 12.79 X | |||
Total Debt | 1.19 M | |||
Debt To Equity | 2.80 % | |||
Current Ratio | 26.45 X | |||
Book Value Per Share | 24.95 X | |||
Cash Flow From Operations | (51.61 M) | |||
Earnings Per Share | (5.18) X | |||
Target Price | 135.0 | |||
Number Of Employees | 26 | |||
Beta | 0.97 | |||
Market Capitalization | 1.45 B | |||
Total Asset | 622.9 M | |||
Net Asset | 622.9 M |
About XSpray Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XSpray Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XSpray Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XSpray Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in XSpray Stock
XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.